Northeast Pharmaceutical Co., Ltd. was selected into the list of construction units of the second batch of drug shortage centralized production base

[industry trends of pharmaceutical network] on December 31, the Ministry of industry and information technology released the list of construction units of the second batch of concentrated production bases of small product drugs (drugs in short supply), and the consortiums led by Northeast Pharmaceutical, North China Pharmaceutical and petrochemicals holding, Yuanda pharmaceutical and Guangzhou Pharmaceutical were selected According to the requirements of the notice, each construction unit shall complete the construction task of the centralized production base of small drug (short drug) according to the construction cycle and responsibility objective requirements, so as to ensure the stable production and supply of small drug (short drug) In recent years, the shortage of drugs has been concerned by the industry Some drugs that are clinically necessary and small in dosage are in short supply, which often make doctors and patients trapped by drugs As a result of the shortage, the price of drugs increases unreasonably, which also increases the burden on patients In order to solve the problem of medicine shortage, the policy combination of our country continued to work In October this year, the opinions on further ensuring the supply and price stability of drugs in short supply was released The opinions implemented policies from the aspects of drug production, purchase, use, storage and price supervision, aiming to achieve the stable production and supply of 100 kinds of drugs in short supply by 2020 There are three factors in drug shortage First, productive factors Due to the small and unstable clinical dosage of some drugs, manufacturers are unwilling to produce them, resulting in drug shortage It is reported that there are few manufacturers of APIs in China Some pharmaceutical raw materials or preparations only have one or two manufacturers Once there is a problem, there will be a shortage Second, policy factors Most of the drugs in short supply are low-cost drugs, women's and children's specialty and emergency (rescue) drugs At present, the supporting policies for the production of these drugs are not perfect, and the enthusiasm of enterprises is not high; third, the factors of malicious monopoly Some manufacturers have maliciously monopolized and deliberately raised market prices, resulting in tight market supply In order to guarantee the supply of drugs, the mode of "drug consortia" came into being In January 2018, the Ministry of industry and information technology of the people's Republic of China, together with the health and Health Commission, the development and Reform Commission and the drug regulatory bureau, jointly organized the construction of the centralized production base of small drug varieties, aiming to solve the problems of small drug variety document number transfer, entrusted production, centralized procurement, supply and demand docking through coordination   Since this year, the Ministry of industry and information technology of the people's Republic of China has released two batches of construction units of concentrated production base of small drug (short drug) The first batch was announced on January 28 this year The specific list includes: a consortium led by Shanghai Pharmaceutical Group Co., Ltd., organized and implemented by Shanghai Pharmaceutical Xinyi Pharmaceutical Co., Ltd and 23 enterprises; a consortium led by China Pharmaceutical Group Co., Ltd The joint venture is organized and implemented by Shanghai Modern Pharmaceutical Co., Ltd and China Biotechnology Co., Ltd.; the joint venture led by Chengdu Beite Pharmaceutical Co., Ltd is organized and implemented by nine enterprises including Chengdu Beite Pharmaceutical Co., Ltd and Chongqing Yaoyou Pharmaceutical Co., Ltd Now 11 months later, the second batch of list has been published, which will further solve the problem of shortage of medicine supply It is understood that from the specific operation of drug consortia, the supply of drug deficient catalogue varieties is generally stable Gu Haoliang, vice president of Shanghai Pharmaceutical Group and director general of the supply guarantee consortium of small product drugs (short of drugs), once said that there were some special situations occasionally, such as the short-term supply problems of some local APIs, and the selected pharmaceutical consortia would make some adjustments in time If there is any shortage of medicine supply within the country, the Ministry of industry and information technology will communicate with it and prepare goods in advance to ensure supply.